SQI Diagnostics Further Cuts Head Count as Possible Shutdown Looms
The company has laid off its chief executive and CSO as it said that it may not be able to continue operations beyond June 15.
Illumina Appeals FTC's Order to Divest Grail, Cites Government Overreach
In its petitioner's brief, Illumina and Grail called the FTC an "unconstitutional agency" and ask the court to revers the commission's decision.
Interpace Biosciences to Stop Offering Pancreatic Cancer Test After Losing CMS Reimbursement
Novitas said in its coverage determination that the test has not demonstrated incremental clinical value in the prognosis of pancreatic cysts and associated cancer.
The new data found that patients identified as low risk by the test received fewer biopsies and were less likely to be diagnosed later with high-grade prostate cancer.
Early Adopters Share Experiences With Grail Cancer Test as Firm Faces New Clinical Questions
Real-world and trial data shored up evidence that the company's multi-cancer detection assay can guide follow-up assessment of patients with a positive result.